You can buy retro NES-style controllers for your Nintendo Switch now

Ever wish your Nintendo Switch looked more like the original NES?

No? Just us? Well, either way, ColorWare thinks someone out there wants a NES-style Switch, because it has just launched the Joy Con Classic, a pair of custom-painted Switch controllers. They’re painted in black and grey to resemble the original NES, but they’re only available for a limited time. And, yes, they function just like any other Switch controllers and work with your existing Switch system.

ColorWare has been releasing custom versions of the Switch for several months, giving consumers the chance to literally switch up the look of their Switch. The company’s new Joy Con Classic features a two-tone design in black and grey with glossy red buttons and accents. But the retro controllers aren’t exactly cheap; they come with a $200 price tag ($120 more than the standard Joy-Cons).

• How to build a SNES Classic Mini for just £50
• SNES Class Mini: Everything you need to know

ColorWare

They feature all the same hardware – accelerometers, gyro sensors, buttons, and even matching wrist straps – but are considerably more expensive, so you’re probably only going to pick these up if you’re diehard Nintendo fan. Keep in mind shipping for the controllers is currently starting at three weeks from time of checkout. If you live in the UK, ColorWare says it ships there, too.

We’ll update this post when we find out UK pricing.

GSK will use supercomputers to develop new drugs

Developing a new drug is a long, complicated and expensive process that takes years before you get to the human trial. There’s a hope that computers will be able to simulate the majority of the process, greatly reducing the cost and time involved. That’s why GlaxoSmithKline is throwing $43 million in the direction of Scottish AI company Exscientia, which promises to use deep learning to find new drugs.

Essentially, Glaxo will hand over some data and a series of objectives, and Exscientia will use its systems to brute force its way to a conclusion. If successful, the process may be able to spit out potential pills that are close to being ready for tests on humans. Exscientia’s Andrew Hopkins claims that his system can find potential treatments in a quarter of the time, at a quarter of the cost.

Of course, there’s still plenty of skepticism that digital drug creation can really supplant old-fashioned methods of research. Being able to simulate chemicals and test their efficacy has not — yet — been proven to be as successful as the traditional method. But if it does work, then expect to hear much more about how big supercomputers are doing away with hundreds of clinical researchers.

Via: Reuters

Source: PR Newswire